⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SYRE News
Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
globenewswire.com
SYRE
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
globenewswire.com
SYRE